BR112018012590A2 - formas cristalinas polimórficas do ácido obeticólico - Google Patents
formas cristalinas polimórficas do ácido obeticólicoInfo
- Publication number
- BR112018012590A2 BR112018012590A2 BR112018012590A BR112018012590A BR112018012590A2 BR 112018012590 A2 BR112018012590 A2 BR 112018012590A2 BR 112018012590 A BR112018012590 A BR 112018012590A BR 112018012590 A BR112018012590 A BR 112018012590A BR 112018012590 A2 BR112018012590 A2 BR 112018012590A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline forms
- obeticolic acid
- polymorphic crystalline
- obeticolic
- acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010008635 Cholestasis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/979,005 US9982008B2 (en) | 2012-06-19 | 2015-12-22 | Preparation and uses of obeticholic acid |
| PCT/US2016/012651 WO2017111979A1 (en) | 2015-12-22 | 2016-01-08 | Polymorphic crystalline forms of obeticholic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018012590A2 true BR112018012590A2 (pt) | 2018-12-04 |
Family
ID=55650649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018012590A BR112018012590A2 (pt) | 2015-12-22 | 2016-01-08 | formas cristalinas polimórficas do ácido obeticólico |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3394081A1 (enExample) |
| JP (1) | JP2018538331A (enExample) |
| KR (1) | KR20180095070A (enExample) |
| CN (1) | CN108495858A (enExample) |
| AU (1) | AU2016375566A1 (enExample) |
| BR (1) | BR112018012590A2 (enExample) |
| CA (1) | CA3009149A1 (enExample) |
| CL (1) | CL2018001720A1 (enExample) |
| CO (1) | CO2018006701A2 (enExample) |
| EA (1) | EA201891491A1 (enExample) |
| IL (1) | IL259998A (enExample) |
| MX (1) | MX2018007776A (enExample) |
| PH (1) | PH12018501318A1 (enExample) |
| SG (1) | SG11201805235XA (enExample) |
| WO (1) | WO2017111979A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105801653B (zh) * | 2014-12-30 | 2018-04-17 | 苏州晶云药物科技有限公司 | 奥贝胆酸的晶型a及其制备方法 |
| WO2018211413A1 (en) * | 2017-05-15 | 2018-11-22 | Dr. Reddy’S Laboratories Limited | Solid forms of obeticholic acid and process for preparation |
| CN109280071A (zh) * | 2017-07-19 | 2019-01-29 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的晶型及其制备方法 |
| CN107383139A (zh) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | 一种3α‑羟基‑7‑氧代‑5β‑胆烷酸新衍生物制备奥贝胆酸的方法 |
| CZ31099U1 (cs) * | 2017-09-05 | 2017-10-17 | Zentiva, K.S. | Krystalické formy (3a,5B,6a,7a)-6-ethyl-3,7- dihydroxycholan-24-ové kyseliny |
| CN109485687A (zh) * | 2017-09-12 | 2019-03-19 | 成都弘达药业有限公司 | 奥贝胆酸的晶型j及其制备方法 |
| WO2019106043A1 (en) | 2017-11-29 | 2019-06-06 | Hexal Ag | Pharmaceutical composition comprising obeticholic acid |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN113264972B (zh) * | 2020-02-14 | 2024-07-12 | 四川科伦药物研究院有限公司 | 一种制备奥贝胆酸的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20050912A1 (it) * | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| CA2877122C (en) * | 2012-06-19 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
| CN106459136B (zh) * | 2014-09-28 | 2018-06-26 | 江苏盛迪医药有限公司 | 一种奥贝胆酸的制备方法 |
| TWI688571B (zh) * | 2014-11-19 | 2020-03-21 | 英商Ｎｚｐ英國有限公司 | 化合物（四） |
| PL3221331T3 (pl) * | 2014-11-19 | 2020-03-31 | NZP UK Limited | Steroidy, 6-alkilo-7-hydroksy-4-en-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr |
| WO2016079518A1 (en) * | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
| CN107108688B (zh) * | 2014-11-19 | 2019-10-29 | Nzp英国有限公司 | 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇 |
-
2016
- 2016-01-08 CA CA3009149A patent/CA3009149A1/en not_active Abandoned
- 2016-01-08 AU AU2016375566A patent/AU2016375566A1/en not_active Abandoned
- 2016-01-08 SG SG11201805235XA patent/SG11201805235XA/en unknown
- 2016-01-08 KR KR1020187020850A patent/KR20180095070A/ko not_active Withdrawn
- 2016-01-08 JP JP2018532396A patent/JP2018538331A/ja active Pending
- 2016-01-08 EA EA201891491A patent/EA201891491A1/ru unknown
- 2016-01-08 EP EP16714049.0A patent/EP3394081A1/en not_active Withdrawn
- 2016-01-08 MX MX2018007776A patent/MX2018007776A/es unknown
- 2016-01-08 BR BR112018012590A patent/BR112018012590A2/pt not_active Application Discontinuation
- 2016-01-08 CN CN201680079793.8A patent/CN108495858A/zh active Pending
- 2016-01-08 WO PCT/US2016/012651 patent/WO2017111979A1/en not_active Ceased
-
2018
- 2018-06-13 IL IL259998A patent/IL259998A/en unknown
- 2018-06-20 PH PH12018501318A patent/PH12018501318A1/en unknown
- 2018-06-22 CL CL2018001720A patent/CL2018001720A1/es unknown
- 2018-06-27 CO CONC2018/0006701A patent/CO2018006701A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3009149A1 (en) | 2017-06-29 |
| CN108495858A (zh) | 2018-09-04 |
| JP2018538331A (ja) | 2018-12-27 |
| CO2018006701A2 (es) | 2018-07-10 |
| EP3394081A1 (en) | 2018-10-31 |
| KR20180095070A (ko) | 2018-08-24 |
| WO2017111979A1 (en) | 2017-06-29 |
| SG11201805235XA (en) | 2018-07-30 |
| CL2018001720A1 (es) | 2018-08-10 |
| AU2016375566A1 (en) | 2018-07-05 |
| IL259998A (en) | 2018-07-31 |
| EA201891491A1 (ru) | 2018-11-30 |
| MX2018007776A (es) | 2018-08-09 |
| PH12018501318A1 (en) | 2019-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018012590A2 (pt) | formas cristalinas polimórficas do ácido obeticólico | |
| BR112018007857A2 (pt) | combinações de gemcabene para o tratamento de doença cardiovascular | |
| IL263843B (en) | Antisense compounds comprising antisense oligonucleotide complementary to a nucleic acid transcript and compositions comprising the same for the treatment of metabolic related diseases | |
| IL264025A (en) | Novel fatty acid-modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| HK1245100A1 (zh) | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 | |
| BR112018003212A2 (pt) | diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3 | |
| DK2838549T3 (da) | Farmaceutisk præparat til forebyggelse eller behandling af ikke-alkoholisk fedtleversygdom | |
| BR112017000418A2 (pt) | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina | |
| MX366925B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
| BR112017013319A2 (pt) | processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 3 poli-insaturados. | |
| BR112017010440A2 (pt) | administração sublingual de riluzol | |
| BR112016021034A2 (pt) | Composição farmacêutica, uso de tal composição, método para tratar uma doença e kit | |
| BR112017010423A2 (pt) | formulação sublingual de riluzol | |
| BR112017006342A2 (pt) | composto de sal de ácido benzenossulfônico, forma em estado sólido cristalino, composição farmacêutica, produto farmacêutico de combinação, método de tratamento de doenças ou condições, uso de um composto de sal de ácido benzenossulfônico, e, processo para preparação de um composto de sal de ácido benzenossulfônico. | |
| BR112017013445A2 (pt) | processo para aumentar a estabilidade de uma composição que compreende ácidos graxos ômega 6 poli-insaturados | |
| BR112017007860A2 (pt) | método para tratar uma doença de gordura no fígado | |
| BR112017003255A2 (pt) | ?precursor para fazer um detergente, detergente e método para sua produção? | |
| BR112016020260A2 (pt) | uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática | |
| CL2014002978A1 (es) | Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa para el tratamiento de trastornos metabólicos | |
| BR112017011304A2 (pt) | Processo para a preparação de ésteres de ácido láctico e ácido 2-hidroxi-3-butenoico ou alfa- hidroxi-análogos de metionina a partir de açúcares | |
| EP3223809A4 (en) | Amino acid compositions for the treatment of symptoms of disease | |
| EP3318261A4 (en) | Use of zoledronic acid to prepare drug treating fatty liver disease | |
| MX2018000883A (es) | Formas cristalinas de bilastina y procedimientos para su preparacion. | |
| BR112016030604B8 (pt) | Processo para preparação de ácidos 3- hidroxipicolínicos | |
| BR112015023302A2 (pt) | processo para a preparação de cristais de ácido dicarboxílico suscetíveis à fluidez a partir de uma solução ou suspensão aquosa do ácido dicarboxílicos em um cristalizador |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |